Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Br J Haematol. 1996;92:479 85. 7. Tomaselli GF, Mahaffey KW, Cuker A, et al. 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral antico- agulants: a report of the American College of Cardiology Task Force on Ex- pert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70:3042 67. 8. Tazarourte K, Riou B, Tremey B, et al. Guideline-concordant administra- tion of prothrombin complex concentrate and vitamin K is associated with decreased mortality in patients with severe bleeding under vitamin K an- tagonist treatment (EPAHK study). Crit Care. 2014;18:R81. 9. Tsu LV, Dienes JE, Dager WE. Vitamin K dosing to reverse warfarin based on INR, route of administration, and home warfarin dose in the acute/ critical care setting. Ann Pharmacother. 2012;46:1617 26. 10. Pernod G, Godi r A, Gozalo C, et al. French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situ- ations (overdose, risk of bleeding, and active bleeding). Thromb Res. 2010;126:e167 74. 11. Weibert RT, Le DT, Kayser SR, et al. Correction of excessive anticoagulation with low-dose oral vitamin K1. Ann Intern Med. 1997;126:959 62. 12. Yiu K-H, Siu C-W, Jim M-H, et al. Comparison of the efficacy and safety profiles of intravenous vitamin K and fresh frozen plasma as treatment of warfarin-related over-anticoagulation in patients with mechanical heart valves. Am J Cardiol. 2006;97:409 11. 13. Khatib R, Ludwikowska M, Witt DM, et al. Vitamin K for reversal of exces- sive vitamin K antagonist anticoagulation: a systematic review and meta- analysis. Blood Adv. 2019;3:789 96. 11.5. Thromboembolic Events With Prosthetic Valves 1. Dangas GD, Weitz JI, Giustino G, et al. Prosthetic heart valve thrombosis. J Am Coll Cardiol. 2016;68:2670 89. 2. 